SPX4,080.11+122.48 3.09%
DIA346.15+7.67 2.27%
IXIC11,468.00+484.22 4.41%

--B. Riley Downgrades Spectrum Pharmaceuticals to Neutral From Buy, Trims PT to $1 From $1.50 Due to Elevated Uncertainty on Poziotinib Prospects, Challenging Near-Term Catalyst Profile

--B. Riley Downgrades Spectrum Pharmaceuticals to Neutral From Buy, Trims PT to $1 From $1.50 Due to Elevated Uncertainty on Poziotinib Prospects, Challenging Near-Term Catalyst Profile

MT Newswires · 11/16/2022 03:21

Please log in to view news